Literature DB >> 3759550

Tumor radiosensitization through reductions in hemoglobin affinity.

D W Siemann, L M Macler.   

Abstract

Alterations in the oxygen (O2) distribution in a tumor due to changes in the quantity of O2 carried in the blood can affect the response of a tumor to radiation. For example, the blood hemoglobin (Hb) level has been shown to be an important prognostic and therapeutic factor in radiation therapy. Another factor affecting the delivery of O2 to tissues is the Hb affinity for O2. Changes in Hb affinity for O2 result in shifts of the Hb-O2 dissociation curve which increase or decrease tissue oxygenation. The aim of the present studies was to determine whether reductions in Hb affinity prior to irradiation could improve the resultant tumor response. KHT sarcomas were irradiated in female C3H/HeJ mice, possessing either normal or reduced Hb affinities for O2 at the time of treatment. Changes in Hb affinity for O2 were induced by keeping tumor-bearing mice in a 12% O2 environment for various periods of time. Erythrocyte 2,3-diphosphoglycerate (2,3 DPG) was measured as an indicator of Hb affinity for O2. After 36 hr of low O2 exposure, 2,3 DPG levels increased 20-30%. This change in 2,3 DPG reflected a proportional decrease in Hb affinity for O2. Following the exposure of 12% O2, the animals were removed from the low O2 chamber and their tumors locally irradiated while the mice breathed air. After irradiation, tumor cell survival was determined using an in vivo to in vitro excision assay. The results indicate that the fraction of hypoxic cells in tumors of mice whose Hb affinity had been reduced prior to irradiation was approximately 3%. By comparison, the hypoxic fraction in tumors irradiated in mice with normal Hb affinities was approximately 15%. Thus, reductions in Hb affinity prior to irradiation can yield significant radiation sensitization in tumors. These findings form the basis for future investigations of the use of pharmacologic methods for the in vivo alteration of the Hb-O2 dissociation curve to improve tumor oxygenation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3759550     DOI: 10.1016/0360-3016(86)90157-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Modifiers of radiosensitivity.

Authors:  A Rojas; J Denekamp
Journal:  Experientia       Date:  1989-01-15

Review 2.  Modulation of the tumor vasculature and oxygenation to improve therapy.

Authors:  Dietmar W Siemann; Michael R Horsman
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

3.  A Multimodal Molecular Imaging Study Evaluates Pharmacological Alteration of the Tumor Microenvironment to Improve Radiation Response.

Authors:  Yoichi Takakusagi; Sarwat Naz; Kaori Takakusagi; Masahiro Ishima; Hiroshi Murata; Keisuke Ohta; Masahiko Miura; Fumio Sugawara; Kengo Sakaguchi; Shun Kishimoto; Jeeva P Munasinghe; James B Mitchell; Murali C Krishna
Journal:  Cancer Res       Date:  2018-10-09       Impact factor: 12.701

4.  RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice.

Authors:  S R Khandelwal; B D Kavanagh; P S Lin; Q T Truong; J Lu; D J Abraham; R K Schmidt-Ullrich
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

Review 5.  The impact of hypoxia and its modification of the outcome of radiotherapy.

Authors:  Michael R Horsman; Jens Overgaard
Journal:  J Radiat Res       Date:  2016-03-16       Impact factor: 2.724

6.  Intracapillary HbO2 saturations in murine tumours and human tumour xenografts measured by cryospectrophotometry: relationship to tumour volume, tumour pH and fraction of radiobiologically hypoxic cells.

Authors:  E K Rofstad; B M Fenton; R M Sutherland
Journal:  Br J Cancer       Date:  1988-05       Impact factor: 7.640

7.  BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice.

Authors:  D J Honess; D E Hu; N M Bleehen
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.